Please assess the completion status of the following clinical trial:

Trial Title: Aripiprazole in Adolescents With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Primary diagnosis of Schizophrenia 1~Exclusion Criteria:~* Patients diagnosed with schizoaffective disorder, major depressive disorder, delirium, or bipolar disorder

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Aripiprazole 10 mg/day Group (Type: ACTIVE_COMPARATOR): Dose was titrated to a target dose of 10 mg/day as follows: starting dose 2 mg/day, increased to 5 mg/day on Day 3, 10 mg/day on Day 5; one dose reduction to 5 mg/day allowed after Day 25
- Aripiprazole 30 mg/day Group (Type: ACTIVE_COMPARATOR): Dose was titrated to a target dose of 30 mg/day as follows: starting dose 2 mg/day, increased to 5 mg/day on Day 3, 10 mg/day on Day 5, 15 mg/day on Day 7, 20 mg/day on Day 9, and 30 mg/day on Day 11; one dose reduction to 15 mg/day allowed after Day 25
- Placebo Group (Type: PLACEBO_COMPARATOR): Participants were given a single pill administered once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).